Zacks: Analysts Anticipate Emergent Biosolutions Inc (EBS) Will Post Quarterly Sales of $182.16 Million

Analysts forecast that Emergent Biosolutions Inc (NYSE:EBS) will report $182.16 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Emergent Biosolutions’ earnings. The highest sales estimate is $184.60 million and the lowest is $179.71 million. Emergent Biosolutions posted sales of $151.66 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.1%. The business is expected to report its next quarterly earnings report after the market closes on Thursday, February 22nd.

According to Zacks, analysts expect that Emergent Biosolutions will report full year sales of $182.16 million for the current financial year. For the next year, analysts anticipate that the firm will post sales of $715.70 million per share. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. During the same quarter in the previous year, the business posted $0.56 EPS. The firm’s revenue was up 4.6% on a year-over-year basis.

Several research analysts have recently issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Emergent Biosolutions in a report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 target price for the company. Chardan Capital upped their target price on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research cut shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $51.00.

In related news, CEO Daniel Abdun-Nabi sold 20,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $45.99, for a total value of $919,800.00. Following the completion of the sale, the chief executive officer now owns 224,134 shares in the company, valued at approximately $10,307,922.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Fuad El-Hibri sold 40,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $40.37, for a total transaction of $1,614,800.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 165,722 shares of company stock valued at $7,219,341. Company insiders own 16.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. raised its position in Emergent Biosolutions by 0.8% in the 2nd quarter. Macquarie Group Ltd. now owns 25,969 shares of the biopharmaceutical company’s stock valued at $881,000 after purchasing an additional 197 shares during the last quarter. Stifel Financial Corp raised its position in Emergent Biosolutions by 3.9% in the 2nd quarter. Stifel Financial Corp now owns 13,572 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 513 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Emergent Biosolutions by 23.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 587 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in Emergent Biosolutions by 2.6% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 36,866 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 917 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in Emergent Biosolutions by 1.0% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 90,099 shares of the biopharmaceutical company’s stock valued at $3,055,000 after purchasing an additional 933 shares during the last quarter. Hedge funds and other institutional investors own 74.31% of the company’s stock.

Emergent Biosolutions (NYSE:EBS) traded down $0.77 during midday trading on Tuesday, reaching $44.44. 733,653 shares of the company’s stock traded hands, compared to its average volume of 324,052. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a 12 month low of $27.94 and a 12 month high of $51.25. The firm has a market cap of $2,200.00, a PE ratio of 27.78, a PEG ratio of 0.96 and a beta of 1.32.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/09/zacks-analysts-anticipate-emergent-biosolutions-inc-ebs-will-post-quarterly-sales-of-182-16-million.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit